{"id":3071,"date":"2022-01-15T18:42:52","date_gmt":"2022-01-15T18:42:52","guid":{"rendered":"https:\/\/lab.research.sickkids.ca\/tabori\/?page_id=3071"},"modified":"2022-02-18T19:18:47","modified_gmt":"2022-02-18T19:18:47","slug":"funding","status":"publish","type":"page","link":"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/","title":{"rendered":"Research Funding"},"content":{"rendered":"

[vc_row css_animation=”right-to-left”][vc_column][vc_column_text]<\/p>\n

Research Funding<\/h1>\n

[\/vc_column_text][vc_column_text]<\/p>\n

Current Funding<\/h2>\n

 <\/p>\n

2021 \u2013 2026\u00a0\u00a0\u00a0 Principal Investigator<\/strong>.\u00a0<\/span>Dissecting the origins and microenvironment of replication repair deficient hypermutant gliomas for novel immune based therapies<\/span>. Canadian Institute of Health Research (CIHR). Principal Investigator:\u00a0<\/span>Tabori, U<\/strong>.\u00a0<\/span>Co- investigators:\u00a0<\/span>Dir<\/span>ks, P., Hawkins, C.,\u00a0<\/span>Gallo, M., Angers, S. <\/span>1,300,000.00 CAD.<\/strong>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2021 \u2013 2023 \u00a0\u00a0 Prinicipal\u00a0Investigator<\/span><\/strong>.\u00a0<\/span>\u00a0<\/span>Molecular Classification of Primary CNS Tumors in Adolescents and Young Adults.\u00a0<\/span>C17 Research Network.<\/span> Principal Investigator: <\/span>Tabori, U<\/strong>. <\/span>Co-applicants:\u00a0<\/span>Hawkins, C., Bennett, J., Lim-Fat,\u00a0<\/span>M<\/span>J.,<\/span>\u00a0Das, S.\u00a0<\/span>72,000 CAD.\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

2020 \u2013 2023 \u00a0\u00a0 Principal\u00a0Investiagor<\/strong><\/span>. Detection and Prevention of Hypermutant Glioma in Children and Young Adults. Canadian Cancer Society\/Canadian Institute of Health Research (CCS\/CIHR). Spark Grant. Principal Investigator: Tabori, U. 150,000 CAD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

 <\/p>\n

2020 \u2013 2023 \u00a0\u00a0 Co-applicant<\/strong><\/span>. Early Detection and Novel Stratification of Pediatric Low-Grade Gliomas by MRI-based Artificial Intelligence. Canadian Cancer Society\/Canadian Institute of Health Research (CCS\/CIHR). Spark Grant. <\/span>Principal Investigator: Khalvati, F.\u00a0Co-applicants: Tabori,U<\/strong>.150,000 CAD<\/strong>. <\/span>\u00a0<\/span><\/p>\n

 <\/p>\n

2020 \u2013 2023 \u00a0\u00a0 Principal Investigator<\/strong>. Landscape of Somatic and Inherited Replication Repair Deficiency towards a Childhood Cancer Vaccine. National Cancer Institute Community Oncology. Research Program Grant. Prinicipal Investigator: Tabori, U<\/strong>. 1,200,000 USD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

 <\/p>\n

2019\u00a0\u2013 2023\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Clinical translation of novel immune-based combination therapies for Paediatric Hypermutant cancers. Stand Up To Cancer (SU2C), Pediatric Catalyst Research Grant. Principal Investigator: <\/span>Tabori, U<\/strong>.\u00a0<\/span>4,000,000.00 CAD.\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

2019 \u2013 2022\u00a0\u00a0\u00a0 Co-Applicant.\u00a0<\/strong>NanoStrng Couner Vantage 3D platform-based complementary diagnositic tests for precision medicine in pediatric cancers. Genome Canada. Principal Investigator: Hawkins C. Co-applicants: Somers G., Tabori U<\/strong>.\u00a03,978,462 CAD.<\/strong><\/span>\u00a0<\/span><\/p>\n

 <\/p>\n

2019 \u2013 2022\u00a0\u00a0\u00a0 Principal Investigator.<\/strong> Biological and pre-clinical studies to enable TIL therapy clinical trial in pediatric hypermutant cancers. V-foundation USA. Principal Investigator: Tabori, U<\/strong>. 600,000 USD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

2018 \u2013 2023\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Biological and translational implications of replication repair deficiency and hyper mutation in human cancer. Canadian Institute of Health Research (CIHR). Principal Investigator: Tabori, U<\/strong>. 1,250,000.00 CAD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

2018 \u2013 2023\u00a0\u00a0\u00a0 Co-Applicant<\/strong>. Molecular based approach to improve outcome for children and young adults with low grade glioma. Canadian Institute of Health Research (CIHR). Operating Grant. Principal Investigator: Hawkins, C. Collaborators: Tabori, U<\/strong>.\u00a01,000,000\u00a0CAD.\u00a0<\/strong><\/span>\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

 <\/p>\n

Completed Funding – within the last 6 years<\/h2>\n

\u00a0<\/strong><\/h1>\n

2020 \u2013 2021\u00a0\u00a0\u00a0 Principal Investigator<\/b>. Alteration of mutagenic gut microbiome for cancer prevention. Pitblado Discovery Grant. Principal Investigator: Tabori,\u00a0U<\/strong>.\u00a060,000 CAD.\u00a0<\/strong><\/p>\n

 <\/p>\n

2019 \u2013 2021\u00a0\u00a0\u00a0 Principal Investigator<\/strong>.\u00a0Catalyzing the University of Toronto as a Global Epicenter for Translational Research and Training. Connaught Global Translational Award. Principal Investigator: Tabori,<\/strong> U<\/strong>.Collaborators: Gotlieb A., Ferenbok J. 200,000 CAD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

 <\/p>\n

2019\u00a0\u00a0 Principal Investigator<\/strong>. A comprehensive clinical and molecular characterization of low grade gliomas in adolescents and young adults. B.R.A.I.N Child. Principal Investigator: Tabori, U<\/strong>. Canada. 25,000 CAD.<\/strong><\/span><\/p>\n

\u00a0<\/span><\/p>\n

2019\u00a0\u00a0 Co-Principal Investigator.<\/strong> A Phase 2 study of Trametinib for patients with pedriatic glioma or plexiform neurofibroma with refactory tumor and activation of the MAPK\/ERK pathway. Canadian Institute of Health Research (CIHR). Principal Investigator: Perrault, S., Tabori, U<\/strong>. 1,500,000 CAD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

2017 \u2013 2019\u00a0\u00a0\u00a0 Principal Investigator.<\/strong> Combined approaches by immune checkpoint inhibition for Hypermutant cancers. American Association for Cancer Research (AACR) and Bristol-Myers Squibb (BMS). Stand Up To Cancer (SU2C) Catalyst research grant. Principal Investigator: <\/span>Tabori, U<\/strong>.<\/strong> 4,000,000 USD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

2017\u00a0\u00a0 Principal Investigator<\/strong>. Minimally invasive diagnostics for therapeutic and disease monitoring in childhood Cancer. Pitbaldo Cancer center grant. Principal Investigator: Tabori,<\/strong> U<\/strong>. 50,000 CAD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

2016 \u2013 2020\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Developmental and predictive companion biomarkers and theraputic monitoring for hypermutant cancers to immune checkpoint inhibition. BioCanRx. Principal Investigator: Tabori, U<\/strong>.\u00a0400,000\u00a0CAD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

\u00a0<\/span><\/p>\n

2016 \u2013 2019\u00a0\u00a0\u00a0 Co-Applicant<\/strong>. Clinical development and translation of genomics-driven pediatric cancer diagnostics using Nano String technology. Genome Canada. Principal Investigator: Hawkins, C. Collaborators: Tabori, U<\/strong>. 600,000 CAD.<\/strong><\/span><\/p>\n

\u00a0<\/span><\/p>\n

2016 \u2013 2018\u00a0\u00a0\u00a0 Principal Investigator.<\/strong> Direct translation of genetic and Immunophenotypic characterization for clinical companion diagnostic and therapeutic monitoring of mismatch repair deficient Ultra-Hypermutant Paediatric cancers to immune checkpoint inhibition. BioCanRX, Enabling Studies program. Principal Investigator: Tabori, U<\/strong>. 750,000 CAD<\/strong>.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2016 \u2013 2017\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Universal novel classification of childhood low grade gliomas using clinic-pathological and biological methods. The PLGA foundation USA. Principal Investigator: Tabori, U<\/strong>.\u00a050,000 CAD<\/strong>.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2016 \u2013 2017\u00a0\u00a0\u00a0 Co-Applicant<\/strong>. Ultra-sensitive minimally invasive diagnostics for therapeutic and disease monitoring in childhood brain tumors. Ontario Centre of Excellence, P.O.P Grant. Principal investigator: Hawkins, C. Collaborators: Tabori, U<\/strong>.\u00a0140,000 CAD<\/strong>.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2015 \u2013 2020\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Targeting the telomere maintenance pathway for cancer diagnostics and therapeutics. Canadian Cancer Research Society. Impact Grant. Principal Investigator: Tabori, U<\/strong>. Collaborators: Kelly, S., Dirks, P., Bristow, R., Shlien, A., Castelo-Branco, P., Mai, S. 1,250,000 CAD<\/strong><\/span>.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2015 \u2013 2018\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Translating genomic discoveries to cure Ultra-Hypermutant mismatch repair deficient brain tumors. Canadian Institute of Health Research (CIHR), Israel- Canada Joint Research Program.\u00a0\u00a0Principal Investigator: Tabori, U<\/strong>. 1,300,000 CAD<\/strong>.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2015 \u2013 2016\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Long term clinical implication of pediatric low grade glioma molecular subgroups (part 2). Making Headway Foundation,\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 USA. Principal Investigator: Tabori, U<\/strong>.\u00a025,000 USD<\/strong>.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2015 \u2013 2016\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Establishment of a mismatch repair zebrafish brain tumor model. B.R.A.I.N. Child.\u00a0Principal Investigator:\u00a0Tabori, U<\/strong>. 25,000\u00a0CAD<\/strong>.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2014 \u2013 2019\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Novel implications of THOR hyper methylation in telomere maintenance and glioma genesis. Canadian Institute of Health Research (CIHR). Principal Investigator: Tabori, U<\/strong>. 990,000 CAD<\/strong>.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2014 \u2013 2016\u00a0\u00a0\u00a0 Principal Investigator.<\/strong> Utilization of THOR hyper methylation for stratification and noninvasive detection of cancer. Canadian Cancer Research Society. Innovation grant. Principal Investigator: Tabori, U<\/strong>.\u00a0200,000 CAD<\/strong>.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

2012 \u2013 2016\u00a0\u00a0\u00a0 Principal Investigator<\/strong>. Clinical and biological implications of Monoallelic gene expression in pediatric malignant brain tumors. Canadian Institute of Health Research (CIHR). Principal Investigator: <\/span>Tabori, U.<\/strong>,<\/span>\u00a0Michael, T. 573,543 CAD.<\/strong><\/span>\u00a0<\/strong><\/p>\n

\u00a0<\/strong>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row css_animation=”right-to-left”][vc_column][vc_column_text] Research Funding [\/vc_column_text][vc_column_text] Current Funding   2021 \u2013 2026\u00a0\u00a0\u00a0 Principal Investigator.\u00a0Dissecting the origins and microenvironment of replication repair deficient hypermutant gliomas for novel immune based therapies. Canadian Institute of Health Research (CIHR). Principal Investigator:\u00a0Tabori, U.\u00a0Co- investigators:\u00a0Dirks, P., Hawkins, C.,\u00a0Gallo, M., Angers, S. 1,300,000.00 CAD.\u00a0 \u00a0 2021 \u2013 2023 \u00a0\u00a0 Prinicipal\u00a0Investigator.\u00a0\u00a0Molecular Classification of Primary…<\/p>\n","protected":false},"author":356,"featured_media":0,"parent":414,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3071","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nResearch Funding - Tabori Lab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Research Funding\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=”right-to-left”][vc_column][vc_column_text] Research Funding [\/vc_column_text][vc_column_text] Current Funding   2021 \u2013 2026\u00a0\u00a0\u00a0 Principal Investigator.\u00a0Dissecting the origins and microenvironment of replication repair deficient hypermutant gliomas for novel immune based therapies. Canadian Institute of Health Research (CIHR). Principal Investigator:\u00a0Tabori, U.\u00a0Co- investigators:\u00a0Dirks, P., Hawkins, C.,\u00a0Gallo, M., Angers, S. 1,300,000.00 CAD.\u00a0 \u00a0 2021 \u2013 2023 \u00a0\u00a0 Prinicipal\u00a0Investigator.\u00a0\u00a0Molecular Classification of Primary…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Tabori Lab\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-18T19:18:47+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/\",\"url\":\"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/\",\"name\":\"Research Funding - Tabori Lab\",\"isPartOf\":{\"@id\":\"https:\/\/lab.research.sickkids.ca\/tabori\/#website\"},\"datePublished\":\"2022-01-15T18:42:52+00:00\",\"dateModified\":\"2022-02-18T19:18:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lab.research.sickkids.ca\/tabori\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sponsors\",\"item\":\"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Research Funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lab.research.sickkids.ca\/tabori\/#website\",\"url\":\"https:\/\/lab.research.sickkids.ca\/tabori\/\",\"name\":\"Tabori Lab\",\"description\":\"Uri Tabori's lab at SickKids Research Institute\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lab.research.sickkids.ca\/tabori\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Research Funding - Tabori Lab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/","og_locale":"en_US","og_type":"article","og_title":"Research Funding","og_description":"[vc_row css_animation=”right-to-left”][vc_column][vc_column_text] Research Funding [\/vc_column_text][vc_column_text] Current Funding   2021 \u2013 2026\u00a0\u00a0\u00a0 Principal Investigator.\u00a0Dissecting the origins and microenvironment of replication repair deficient hypermutant gliomas for novel immune based therapies. Canadian Institute of Health Research (CIHR). Principal Investigator:\u00a0Tabori, U.\u00a0Co- investigators:\u00a0Dirks, P., Hawkins, C.,\u00a0Gallo, M., Angers, S. 1,300,000.00 CAD.\u00a0 \u00a0 2021 \u2013 2023 \u00a0\u00a0 Prinicipal\u00a0Investigator.\u00a0\u00a0Molecular Classification of Primary…","og_url":"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/","og_site_name":"Tabori Lab","article_modified_time":"2022-02-18T19:18:47+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/","url":"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/","name":"Research Funding - Tabori Lab","isPartOf":{"@id":"https:\/\/lab.research.sickkids.ca\/tabori\/#website"},"datePublished":"2022-01-15T18:42:52+00:00","dateModified":"2022-02-18T19:18:47+00:00","breadcrumb":{"@id":"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lab.research.sickkids.ca\/tabori\/"},{"@type":"ListItem","position":2,"name":"Sponsors","item":"https:\/\/lab.research.sickkids.ca\/tabori\/sponsors\/"},{"@type":"ListItem","position":3,"name":"Research Funding"}]},{"@type":"WebSite","@id":"https:\/\/lab.research.sickkids.ca\/tabori\/#website","url":"https:\/\/lab.research.sickkids.ca\/tabori\/","name":"Tabori Lab","description":"Uri Tabori's lab at SickKids Research Institute","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lab.research.sickkids.ca\/tabori\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/lab.research.sickkids.ca\/tabori\/wp-json\/wp\/v2\/pages\/3071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lab.research.sickkids.ca\/tabori\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/lab.research.sickkids.ca\/tabori\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/lab.research.sickkids.ca\/tabori\/wp-json\/wp\/v2\/users\/356"}],"replies":[{"embeddable":true,"href":"https:\/\/lab.research.sickkids.ca\/tabori\/wp-json\/wp\/v2\/comments?post=3071"}],"version-history":[{"count":0,"href":"https:\/\/lab.research.sickkids.ca\/tabori\/wp-json\/wp\/v2\/pages\/3071\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/lab.research.sickkids.ca\/tabori\/wp-json\/wp\/v2\/pages\/414"}],"wp:attachment":[{"href":"https:\/\/lab.research.sickkids.ca\/tabori\/wp-json\/wp\/v2\/media?parent=3071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}